Medical experts and researchers have renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) [1].
The change aims to shift the clinical focus from a localized ovarian issue to a systemic condition. By highlighting the endocrine and metabolic components, health professionals hope to improve the accuracy of diagnoses and the effectiveness of long-term treatment strategies.
For decades, the term PCOS suggested that the primary problem resided within the ovaries. However, the new designation, PMOS, acknowledges that the syndrome is a complex interaction of hormonal and metabolic dysfunction [1]. This shift is intended to increase awareness of the condition's broader implications for a patient's overall health, including its impact on insulin and other hormones [2].
The scale of the condition is significant. Reports indicate the syndrome affects 170 million women worldwide [2], though other estimates describe the impact as affecting tens of millions of women [3]. In Canada, the condition affects one in 10 women [2].
Researchers said the update is necessary to correct decades of misinformation regarding the nature of the disorder [4]. Because the condition involves multiple endocrine systems, the name PMOS more accurately describes the physiological reality of the patients. The updated terminology is expected to guide clinicians toward a more holistic approach to care, one that addresses metabolic health alongside reproductive symptoms [5].
This transition reflects a growing consensus in the medical community that the ovaries are often a site of the symptoms rather than the sole source of the disease [6]. By renaming the syndrome, experts intend to reduce the stigma and confusion associated with the previous name while encouraging more comprehensive screening for metabolic risks.
“PCOS has been renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS)”
The transition from PCOS to PMOS represents a fundamental shift in medical understanding, moving the condition from a reproductive-centric diagnosis to a metabolic one. By redefining the syndrome, the medical community is signaling that treatment must prioritize hormonal and endocrine stability—such as insulin regulation—rather than focusing solely on ovarian cysts. This may lead to earlier interventions for metabolic disorders and a decrease in the misdiagnosis of systemic symptoms as purely gynecological.
